BIOMAT Database Logo BIOMAT Database Logo

Development of a smartphone-based quantum dot lateral flow immunoassay strip for ultrasensitive detection of anti-SARS-CoV-2 IgG and neutralizing antibodies. 2022

Jinfeng Li, and Bochao Liu, and Xi Tang, and Ze Wu, and Jinhui Lu, and Chaolan Liang, and Shuiping Hou, and Ling Zhang, and Tingting Li, and Wei Zhao, and Yongshui Fu, and Yuebin Ke, and Chengyao Li
Department of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China; Shenzhen Key Laboratory of Molecular Epidemiology, Shenzhen Center for Disease Control and Prevention, Shenzhen, China.

BACKGROUND As several vaccines for SARS-CoV-2 have been developed, a large proportion of individuals have been vaccinated worldwide so far. The rapid and accurate immunoassays are urgently needed for detecting the specific virus-neutralizing antibody (NAb), which reflect the protective effect of the vaccines among different populations. METHODS In this study, we designed a quantum dot lateral flow immunoassay strip (QD-LFIA) for smartphones for the detection of specific IgG or neutralizing antibodies in SARS-CoV-2 in human serum or whole blood samples. The recombinant receptor binding domain of the SARS-CoV-2 spike protein was used as the antigen to combine with NAb or angiotensin-converting enzyme 2. RESULTS Among 81 patients who recovered from COVID-19 who were diagnosed using the nucleic acid test initially, 98.8% (80/81) were positive for IgG and 88.9% (72/81) were positive for NAb by QD-LFIA. Among 64 individuals inoculated with inactivated vaccines and six subunit vaccines, 90% (63/70) were positive for IgG and 82.9% (58/70) were positive for NAb by QD-LFIA, whereas no cross-reaction was found in 150 healthy blood donors, two patients with influenza B, and three patients with common cold. CONCLUSIONS The established platform could achieve a rapid and accurate detection of NAb specific to SARS-CoV-2, which could be used for detecting the protective effect of the vaccines in areas of world that currently affected by the pandemic.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007118 Immunoassay A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance. Immunochromatographic Assay,Assay, Immunochromatographic,Assays, Immunochromatographic,Immunoassays,Immunochromatographic Assays
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068997 Smartphone A cell phone with advanced computing and connectivity capability built on an operating system. Smart Phone,Smart Phones,Phones, Smart,Smartphones
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000086663 COVID-19 Vaccines Vaccines or candidate vaccines containing SARS-CoV-2 component antigens, genetic materials, or inactivated SARS-CoV-2 virus, and designed to prevent COVID-19. 2019 Novel Coronavirus Vaccine,2019 Novel Coronavirus Vaccines,2019-nCoV Vaccine,2019-nCoV Vaccines,COVID 19 Vaccine,COVID-19 Vaccine,COVID-19 Virus Vaccine,COVID-19 Virus Vaccines,COVID19 Vaccine,COVID19 Vaccines,COVID19 Virus Vaccine,COVID19 Virus Vaccines,Coronavirus Disease 2019 Vaccine,Coronavirus Disease 2019 Vaccines,Coronavirus Disease 2019 Virus Vaccine,Coronavirus Disease 2019 Virus Vaccines,Coronavirus Disease-19 Vaccine,Coronavirus Disease-19 Vaccines,SARS Coronavirus 2 Vaccines,SARS-CoV-2 Vaccine,SARS-CoV-2 Vaccines,SARS2 Vaccine,SARS2 Vaccines,2019 nCoV Vaccine,2019 nCoV Vaccines,COVID 19 Vaccines,COVID 19 Virus Vaccine,COVID 19 Virus Vaccines,Coronavirus Disease 19 Vaccine,Coronavirus Disease 19 Vaccines,SARS CoV 2 Vaccine,SARS CoV 2 Vaccines,Vaccine, 2019-nCoV,Vaccine, COVID 19,Vaccine, COVID-19,Vaccine, COVID-19 Virus,Vaccine, COVID19,Vaccine, COVID19 Virus,Vaccine, Coronavirus Disease-19,Vaccine, SARS-CoV-2,Vaccine, SARS2,Vaccines, 2019-nCoV,Vaccines, COVID-19,Vaccines, COVID-19 Virus,Vaccines, COVID19,Vaccines, COVID19 Virus,Vaccines, Coronavirus Disease-19,Vaccines, SARS-CoV-2,Vaccines, SARS2,Virus Vaccine, COVID-19,Virus Vaccine, COVID19,Virus Vaccines, COVID-19,Virus Vaccines, COVID19
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D045663 Quantum Dots Nanometer sized fragments of semiconductor crystalline material which emit PHOTONS. The wavelength is based on the quantum confinement size of the dot. They can be embedded in MICROBEADS for high throughput ANALYTICAL CHEMISTRY TECHNIQUES. Nanocrystals, Semiconductor,Semiconductor Nanocrystals,Semiconductor Nanoparticles,Dot, Quantum,Dots, Quantum,Nanocrystal, Semiconductor,Nanoparticle, Semiconductor,Nanoparticles, Semiconductor,Quantum Dot,Semiconductor Nanocrystal,Semiconductor Nanoparticle
D057134 Antibodies, Neutralizing Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus. Neutralizing Antibodies,Antibody, Neutralizing,Neutralizing Antibody

Related Publications

Jinfeng Li, and Bochao Liu, and Xi Tang, and Ze Wu, and Jinhui Lu, and Chaolan Liang, and Shuiping Hou, and Ling Zhang, and Tingting Li, and Wei Zhao, and Yongshui Fu, and Yuebin Ke, and Chengyao Li
Development of a quantum dot-based lateral flow immunoassay strip for rapid and sensitive detection of SARS-CoV-2 neutralizing antibodies.
December 2023, Scientific reports,
Jinfeng Li, and Bochao Liu, and Xi Tang, and Ze Wu, and Jinhui Lu, and Chaolan Liang, and Shuiping Hou, and Ling Zhang, and Tingting Li, and Wei Zhao, and Yongshui Fu, and Yuebin Ke, and Chengyao Li
Development of a lateral flow immunoassay strip for rapid detection of IgG antibody against SARS-CoV-2 virus.
August 2020, The Analyst,
Jinfeng Li, and Bochao Liu, and Xi Tang, and Ze Wu, and Jinhui Lu, and Chaolan Liang, and Shuiping Hou, and Ling Zhang, and Tingting Li, and Wei Zhao, and Yongshui Fu, and Yuebin Ke, and Chengyao Li
Development and evaluation of a Lateral flow immunoassay (LFIA) prototype for the detection of IgG anti-SARS-CoV-2 antibodies.
May 2024, Heliyon,
Jinfeng Li, and Bochao Liu, and Xi Tang, and Ze Wu, and Jinhui Lu, and Chaolan Liang, and Shuiping Hou, and Ling Zhang, and Tingting Li, and Wei Zhao, and Yongshui Fu, and Yuebin Ke, and Chengyao Li
Ultrabright nanoparticle-labeled lateral flow immunoassay for detection of anti-SARS-CoV-2 neutralizing antibodies in human serum.
September 2022, Biomaterials,
Jinfeng Li, and Bochao Liu, and Xi Tang, and Ze Wu, and Jinhui Lu, and Chaolan Liang, and Shuiping Hou, and Ling Zhang, and Tingting Li, and Wei Zhao, and Yongshui Fu, and Yuebin Ke, and Chengyao Li
Simultaneous Detection of SARS-CoV-2 IgG/IgM Antibodies, Using Gold Nanoparticles-Based Lateral Flow Immunoassay.
October 2021, Monoclonal antibodies in immunodiagnosis and immunotherapy,
Jinfeng Li, and Bochao Liu, and Xi Tang, and Ze Wu, and Jinhui Lu, and Chaolan Liang, and Shuiping Hou, and Ling Zhang, and Tingting Li, and Wei Zhao, and Yongshui Fu, and Yuebin Ke, and Chengyao Li
Sensitive and Simultaneous Detection of SARS-CoV-2-Specific IgM/IgG Using Lateral Flow Immunoassay Based on Dual-Mode Quantum Dot Nanobeads.
December 2020, Analytical chemistry,
Jinfeng Li, and Bochao Liu, and Xi Tang, and Ze Wu, and Jinhui Lu, and Chaolan Liang, and Shuiping Hou, and Ling Zhang, and Tingting Li, and Wei Zhao, and Yongshui Fu, and Yuebin Ke, and Chengyao Li
Overlaid Lateral Flow Immunoassay for the Simultaneous Detection of Two Variant-Specific SARS-CoV-2 Neutralizing Antibodies.
March 2024, Analytical chemistry,
Jinfeng Li, and Bochao Liu, and Xi Tang, and Ze Wu, and Jinhui Lu, and Chaolan Liang, and Shuiping Hou, and Ling Zhang, and Tingting Li, and Wei Zhao, and Yongshui Fu, and Yuebin Ke, and Chengyao Li
Rapid and Sensitive Detection of anti-SARS-CoV-2 IgG, Using Lanthanide-Doped Nanoparticles-Based Lateral Flow Immunoassay.
May 2020, Analytical chemistry,
Jinfeng Li, and Bochao Liu, and Xi Tang, and Ze Wu, and Jinhui Lu, and Chaolan Liang, and Shuiping Hou, and Ling Zhang, and Tingting Li, and Wei Zhao, and Yongshui Fu, and Yuebin Ke, and Chengyao Li
A Lateral Flow Immunoassay Coupled with a Spectrum-Based Reader for SARS-CoV-2 Neutralizing Antibody Detection.
February 2022, Vaccines,
Jinfeng Li, and Bochao Liu, and Xi Tang, and Ze Wu, and Jinhui Lu, and Chaolan Liang, and Shuiping Hou, and Ling Zhang, and Tingting Li, and Wei Zhao, and Yongshui Fu, and Yuebin Ke, and Chengyao Li
Fluorescence-Quenching Lateral Flow Immunoassay for "Turn-On" and Sensitive Detection of Anti-SARS-Cov-2 Neutralizing Antibodies in Human Serum.
January 2024, Advanced science (Weinheim, Baden-Wurttemberg, Germany),
Copied contents to your clipboard!